健康元：关于药品注册上市许可申请获受理的提示性公告

Core Viewpoint - The announcement indicates that the company’s subsidiary, Lijun Pharmaceutical Group Co., Ltd., has received acceptance from the National Medical Products Administration for the domestic production registration of the drug JP-1366 tablets [1]. Group 1 - The company, Health元, announced on August 15 that its subsidiary, Lijun Pharmaceutical Group, received a notice of acceptance from the National Medical Products Administration [1]. - The acceptance number for the registration application of JP-1366 tablets is CYHS2502991 [1].